anti-HER2 CAR NK-cell therapy (NKGen Biotech/Nkmax)

N/A

Report date: 2025/06/11 10:30:39

Base Information

Drug Nameanti-HER2 CAR NK-cell therapy (NKGen Biotech/Nkmax)
Drug Alias NameHER2-CAR-SNK-02
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulatorsImmunostimulantsNatural killer cells stimulants
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNKGen Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesNKMAX Co LtdNKGen Biotech Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A